Welcome to our dedicated page for Co-Diagnostics SEC filings (Ticker: CODX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Co-Diagnostics, Inc. filings document a molecular diagnostics company’s operating results, material events, governance actions, and capital-structure disclosures. Recent 8-K filings cover financial results, Regulation FD disclosures, non-GAAP presentation references, Nasdaq listing-rule matters, and other corporate events tied to the company’s common stock.
Proxy and material-event filings also describe shareholder voting matters, including authorization for a reverse stock split, along with governance procedures and security-structure changes. The filing record links the company’s Co-Dx PCR platform, clinical and regulatory disclosures, commercialization activities, and public-company reporting obligations with risk, liquidity, listing, and ownership-related disclosure categories.
Co-Diagnostics, Inc. ownership disclosure: a Schedule 13G filed by Jane Street Group, LLC and its subsidiaries reports 236,359 shares of Common Stock (CUSIP 189763204) representing 6.4% of the class as of 05/28/2026. The filing attributes shared voting and shared dispositive power over those 236,359 shares. Subsidiary breakdown: Jane Street Capital, LLC holds 189,817 shares (5.2%) and Jane Street Global Trading, LLC holds 46,542 shares (1.3%). The schedule is signed by Jeremy Kahn on 06/03/2026.
Co-Diagnostics, Inc. filed a registration statement to permit resale by selling stockholders of up to 4,942,341 shares of its common stock, comprised of 54,915 PIPE Shares, 1,592,532 Pre-Funded Warrant Shares and 3,294,894 Common Warrant Shares. The selling holders acquired the securities in a private placement on May 21, 2026. The Company will not receive proceeds from resales, but could receive up to approximately $5.18 million if the Warrants are exercised for cash. Shares outstanding were 3,685,314 as of May 27, 2026. The registration permits the selling stockholders to dispose of shares under various sale methods described in the Plan of Distribution.
Co-Diagnostics, Inc. Chief Executive Officer Dwight H. Egan reported compensation-related equity activity involving common stock and restricted stock units. On May 23, 2026, 1,633 common shares were disposed of at $5.07 per share in a mandated “sell to cover” transaction to satisfy tax withholding obligations tied to RSU vesting, described as not a discretionary trade by the reporting person.
On the same date, he received a grant of 4,584 common shares at no cost and exercised 4,584 restricted stock units into common stock. After these transactions, he directly holds 29,526 common shares and 9,166 restricted stock units.
Co-Diagnostics, Inc. Chief Financial Officer Brian Lee Brown reported routine equity compensation activity involving common stock and restricted stock units. On May 23, 2026, he disposed of 1,350 shares of common stock at $5.07 per share in a transaction described as required to cover tax withholding obligations through a mandated “sell to cover” election under the company’s equity plans, not a discretionary trade.
On the same date, he acquired 3,750 shares of common stock at $0.00 per share as a grant or award, tied to the vesting and settlement of restricted stock units. He also exercised 3,750 restricted stock units into common stock, with remaining derivative holdings reported as 7,500 restricted stock units following the transaction sequence. After these transactions, Brown directly held 23,729 shares of common stock. The activity reflects standard compensation vesting and tax settlement rather than open-market buying or selling.
Co-Diagnostics, Inc. president Richard David Abbott reported routine equity compensation activity involving restricted stock units. He exercised 1,890 restricted stock units into common shares at a stated price of $0.00 per share and received these as a grant or award. On the same date, 680 common shares were disposed of to the issuer at $5.07 per share to cover tax withholding obligations, as required under the company’s equity incentive plan, rather than as a discretionary trade. Following these transactions, he directly held 4,097 shares of common stock.
Co-Diagnostics, Inc. director Edward L. Murphy reported equity compensation activity. He received a grant of 1,695 shares of common stock at $0.00 per share, classified as a grant or award. On the same date, he exercised 1,695 restricted stock units into common stock. Following these transactions, he directly holds 11,084 shares of common stock and 4,000 restricted stock units, reflecting both current ownership and remaining stock-based incentives.
Co-Diagnostics, Inc. director Richard S. Serbin reported equity compensation activity involving restricted stock units. On May 23, 2026, he acquired 1,695 shares of Common Stock at $0.00 per share through a grant and related RSU conversion, rather than an open‑market purchase. After this transaction, he directly holds 10,751 Common shares and 4,000 restricted stock units. The footnotes explain these RSUs were awarded under the company’s 2015 Long Term Incentive Plan with scheduled vesting in six semiannual installments across multiple grant dates.
Co-Diagnostics, Inc. director Eugene Durenard received 1,695 shares of common stock as a stock award and vested restricted stock units that converted into the same number of shares on May 23. These compensation-related transactions were at a reported price of $0.00 per share.
After the award and RSU conversion, Durenard directly holds 10,668 shares of common stock and 4,000 restricted stock units. The RSUs relate to grants of 2,334, 3,667 and 4,167 units made in 2023, 2024 and 2025 under the company’s 2015 Long Term Incentive Plan, vesting in semiannual installments.
Co-Diagnostics, Inc. director James B. Nelson acquired 1,695 shares of Common Stock on May 23, 2026 through a stock grant with a reported price of $0.00 per share, increasing his direct holdings to 10,668 common shares. On the same date, he exercised 1,695 Restricted Stock Units into Common Stock, and the filing shows 4,000 Restricted Stock Units remaining under his direct ownership, linked to awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan that vest in six equal installments every six months.